BioInvent International AB has carried out a primary issuance of shares of approximately SEK 962 million at a subscription price of SEK 50.36 per share.
BioInvent International AB is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.
Kempen & Co and Pareto Securities acted as Joint Global Coordinators. Baker McKenzie acted as legal advisor to Kempen and Pareto Securities as to Swedish and US law. Joakim Falkner, Johanna Flink and Ian Gulam from Baker McKenzie's Capital Markets team in Stockholm were involved in the transaction, as well as Adam Farlow and Charles Farnsworth from the Capital Markets team in London and Paul DePasquale from the Tax team in New York.